Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

The trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.

This triggered the development of RNA interference as a tool, and with it came a myriad of investigations into the function of genes. For researchers working with prokaryotes it is now 1998.

RNAi is a fundamental cellular mechanism for silencing gene expression that can be harnessed for the development of new drugs 1,2. The reduction in expression of pathological proteins through RNAi ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Researchers uncover how 12-hour biological rhythms operate in mammals, exploring their unique mechanisms and potential ...

Bicara Therapeutics presented data from an ongoing, 28-patient trial of its drug showing median overall survival of over 21 ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Symmetry is a fundamental characteristic of most multi-cell animals. However, the cell division of embryonic cells is ...

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his price target from $400 to $500.